about
Clinical outcome measures in juvenile idiopathic arthritisSeeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study.An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus ErythematoGlucocorticoids in juvenile idiopathic arthritis.Advances in biomarkers for paediatric rheumatic diseases.A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis.Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases.Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score.Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.Development and validation of a composite disease activity score for juvenile idiopathic arthritis.Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children.Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients.Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis.Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis.A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report.Prevalence of overweight and obesity in 2- to 6-year-old Italian childrenDevelopment and testing of reduced joint counts in juvenile idiopathic arthritisEvaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritisMRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritisFactors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanerceptWhole-body MRI in the assessment of disease activity in juvenile dermatomyositisDefining criteria for disease activity states in juvenile idiopathic arthritisPaediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain?Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity scoreUnraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas--Key to Understanding Etiology and Genetic Factors?Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic ArthritisEstablishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop
P50
Q26752701-8C2F5425-0056-43E9-92D5-D2B3E2E6AC45Q36552356-97654AD0-ACD7-4C31-AB75-09D301E3B28AQ37834144-56C7D34A-B217-4BAA-98DC-1C64958A62EEQ38010353-8095279F-14FE-488E-9555-044217904DD0Q38250159-B48375AC-B532-45C0-A7F8-DA3B7E0AB8E8Q38289816-2244F79E-EB70-4313-8D5A-898075938BF6Q38691413-67988359-031B-49A3-A2D2-893C526668D5Q38697343-60E9F44E-1365-463B-B510-A2B2889FB6B3Q43484603-24C0636D-29E1-4761-8BA6-CDF918D9BE8AQ45328485-3DAD9628-86D2-4853-981B-D4E57C1BD40DQ46030916-C17AC947-ED41-4A05-AFE7-A0D9E76F8844Q46871104-511CEAE7-A389-4BF1-8FAB-E5A25DD03746Q46966656-66971E2E-3A43-40A9-8919-F81E377778B2Q46966710-19741505-1CD8-4BF9-B7DA-77F0F61790D4Q48264478-1DD5603F-C120-4227-ADB9-2E22849CC1CCQ51134166-9DBA628A-7405-4DEA-BB2C-00777CAFF57FQ53047736-DDA5849D-8856-4DA1-90DE-A5F97A09CF21Q79949159-1E77417A-B5CE-4023-901E-6E636EC001ACQ83327207-DB2D88BE-EBB7-454B-8263-0C3976E73226Q84413776-A9AA0A3F-145F-4569-9E33-CD41AD737CA4Q84524302-45EF96EE-3FE2-4CB5-8F9F-571DED37D3D6Q85592184-F34911A7-1BE0-4FEE-8037-13CB8B3DFD45Q86701418-3F38A33A-C7F8-4015-913C-B3C3E68AAFFEQ86895370-339383D7-7396-4C98-85D3-76F5115417F2Q87035681-0BF791B8-E764-4B6E-B456-735B2489D2B3Q88187233-46B386F5-2F2F-47C7-A24E-65EB4599564EQ89105649-FCB68CB4-B0A5-47D6-94E6-BEC530F415BFQ91062294-6D1E4E41-471E-4593-B775-3176A0FFE14EQ91633732-E97C6580-4567-4904-BE34-9B1F8B3D67BD
P50
description
researcher ORCID ID = 0000-0002-0065-7614
@en
wetenschapper
@nl
name
Alessandro Consolaro
@ast
Alessandro Consolaro
@en
Alessandro Consolaro
@es
Alessandro Consolaro
@nl
type
label
Alessandro Consolaro
@ast
Alessandro Consolaro
@en
Alessandro Consolaro
@es
Alessandro Consolaro
@nl
prefLabel
Alessandro Consolaro
@ast
Alessandro Consolaro
@en
Alessandro Consolaro
@es
Alessandro Consolaro
@nl
P106
P1153
12345480600
P21
P31
P496
0000-0002-0065-7614